Christine Y. Chung, DO, and colleagues report on the next-generation sequence (NGS) testing status of 77 patients referred to their practice for phase 1 study enrollment. It seems in the case of both community and academic practices, in their Colorado area referral zone, about half the patients had previously received either tumor or circulating tumor (ct)DNA testing for actionable mutations.
Although the authors point out the rate of sequencing is approximately equal in the 2 settings, my question is why physicians are even doing this expensive testing. Read more . . .